COVID-19

Corona Virus Infection

SARS-CoV 2

Coronavirus

Coronavirus Infection

Treatment will be sprayed orally twice a day for the first 2 days in the treatment period

ArtemiC

Placebo

Hillel Yaffe Medical Center

Nazareth Hospital EMMS

Rambam Health Care Campus

A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19

patient will be assessed using a scoring table for changes in clinical signs

Adverse events caused by the study drug will be assessed

MGC Pharmaceuticals d.o.o

Patients will be randomized in a manner of 2:1 for study drug (ArteminC) and Standard of Care to Placebo and Standard of Care.
Patient study period will last 2 weeks. During this time, patients will be monitored for adverse events.
There will be a follow up period (until hospital discharge) in order to check side effects and study drug efficacy

25 participants with radiopaque stones (Calcium Oxalate) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)

25 participants with radiopaque stones (Calcium Oxalate) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8)

25 participants with radiolucent stones (Uric acid) treated with Luban (AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma)

25 participants with radiolucent stones (Uric acid) treated with Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 7.0-7.2

Renal Stones

AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma

AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)

Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)

Potassium Sodium Hydrogen Citrate

Mohamed Salim Ahmed Al-Marhoon

Treatment of Renal Stones With Frankincense (Luban)

Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial

The participants intolerance of the treatment or development of side effects that are not known complications of the presence of stones or new adverse reactions

boswellia microphylla/кали

A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19

Treatment of Renal Stones With Frankincense (Luban)

Шинжлэх ухаанаар баталгаажсан эмийн өвс ургамлын бүрэн мэдээллийн сан